Christine Marosi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7483215/publications.pdf

Version: 2024-02-01

190 papers	35,943 citations	36203 51 h-index	3815 178 g-index
225 all docs	225 docs citations	225 times ranked	31863 citing authors

#	Article	IF	Citations
1	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine, 2005, 352, 987-996.	13.9	17,395
2	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, The, 2009, 10, 459-466.	5.1	6,451
3	Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncology, The, 2012, 13, 916-926.	5.1	1,075
4	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology, The, 2017, 18, e315-e329.	5.1	816
5	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncology, The, 2017, 18, 1373-1385.	5.1	776
6	Prediction of venous thromboembolism in cancer patients. Blood, 2010, 116, 5377-5382.	0.6	643
7	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology, 2015, 17, 1064-1075.	0.6	485
8	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2019, 20, e566-e581.	5.1	458
9	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, The, 2016, 17, 1521-1532.	5.1	396
10	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology, 2017, 19, 162-174.	0.6	381
11	Meningioma. Critical Reviews in Oncology/Hematology, 2008, 67, 153-171.	2.0	301
12	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 2012, 124, 547-560.	3.9	274
13	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 2015, 21, 2057-2064.	3.2	264
14	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nature Medicine, 2018, 24, 1611-1624.	15.2	229
15	Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro-Oncology, 2017, 19, 1460-1468.	0.6	213
16	European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncology, The, 2017, 18, e330-e340.	5.1	195
17	Antiâ€O6â€Methylguanineâ€Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*. Brain Pathology, 2008, 18, 520-532.	2.1	189
18	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastomaâ€”results from the DIRECTOR trial. Neuro-Oncology, 2016, 18, 549-556.	0.6	187

#	Article	IF	Citations
19	Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart, 2015, 101, 1874-1880.	1.2	181
20	P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. Journal of Neuro-Oncology, 2005, 72, 255-260.	1.4	176
21	Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood, 2017, 129, 1831-1839.	0.6	164
22	Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathologica, 2012, 123, 205-222.	3.9	163
23	A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget, 2013, 4, 502-530.	0.8	152
24	5-Aminolevulinic Acid Induced Fluorescence Is a Powerful Intraoperative Marker for Precise Histopathological Grading of Gliomas with Non-Significant Contrast-Enhancement. PLoS ONE, 2013, 8, e76988.	1.1	138
25	Vascular Patterns in Glioblastoma Influence Clinical Outcome and Associate with Variable Expression of Angiogenic Proteins: Evidence for Distinct Angiogenic Subtypes. Brain Pathology, 2003, 13, 133-143.	2.1	132
26	Venous thromboembolism and survival in patients with high-grade glioma. Neuro-Oncology, 2007, 9, 89-95.	0.6	119
27	Clinical fMRI: Evidence for a 7T benefit over 3T. NeuroImage, 2011, 57, 1015-1021.	2.1	110
28	Challenge of cancer in the elderly. ESMO Open, 2016, 1, e000020.	2.0	107
29	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806.	3.2	105
30	Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Thrombosis and Haemostasis, 2014, 111, 670-678.	1.8	88
31	Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies. Neurosurgical Review, 2012, 35, 381-391.	1.2	86
32	Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biology, 2015, 16, 16.	3.8	82
33	Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer. British Journal of Haematology, 2019, 186, 311-320.	1.2	82
34	Neurocognitive training in patients with high-grade glioma: a pilot study. Journal of Neuro-Oncology, 2010, 97, 109-115.	1.4	78
35	Influence of adjunctive classical homeopathy on global health status and subjective wellbeing in cancer patients â€“ A pragmatic randomized controlled trial. Complementary Therapies in Medicine, 2015, 23, 309-317.	1.3	78
36	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 2018, 135, 601-615.	3.9	76

#	Article	IF	Citations
37	A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro-Oncology, 2008, 10, 1019-1024.	0.6	74
38	The caregiversâ€™ perspective on the end-of-life phase of glioblastoma patients. Journal of Neuro-Oncology, 2013, 112, 403-411.	1.4	72
39	Expression of Telomeres in Astrocytoma WHO Grade 2 to 4: TERRA Level Correlates with Telomere Length, Telomerase Activity, and Advanced Clinical Grade. Translational Oncology, 2012, 5, 56-IN4.	1.7	71
40	Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. Cancer Genetics and Cytogenetics, 1992, 61, 14-25.	1.0	70
41	The end-of-life phase of high-grade glioma patients: a systematic review. Supportive Care in Cancer, 2014, 22, 847-857.	1.0	68
42	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. Cancers, 2018, 10, 372.	1.7	67
43	Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clinical and Experimental Metastasis, 2013, 30, 357-368.	1.7	66
44	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. PLoS ONE, 2014, 9, e111440.	1.1	64
45	Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro-Oncology, 2014, 16, 1645-1651.	0.6	63
46	Plasma MicroRNA-21 Concentration May Be a Useful Biomarker in Glioblastoma Patients. Cancer Investigation, 2012, 30, 615-621.	0.6	60
47	Trabectedin has promising antineoplastic activity in highâ€grade meningioma. Cancer, 2012, 118, 5038-5049.	2.0	57
48	A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro-Oncology, 2014, 16, 92-102.	0.6	57
49	Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growthâ€inhibitory and VEGFâ€suppressive effects of rapamycin in leukemic cells. FASEB Journal, 2005, 19, 960-962.	0.2	56
50	Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. Journal of Neuro-Oncology, 2003, 63, 55-61.	1.4	53
51	Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thrombosis Research, 2013, 131, 162-165.	0.8	53
52	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro-Oncology, 2016, 18, 401-407.	0.6	53
53	Seven Novel and Stable Translocations Associated with Oncogenic Gene Expression in Malignant Melanoma. Neoplasia, 2005, 7, 303-311.	2.3	52
54	Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurgical Review, 2013, 36, 45-56.	1.2	48

#	Article	IF	Citations
55	[11C] Methionine and [18F] Fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. Journal of Neuro-Oncology, 2007, 84, 305-314.	1.4	44
56	Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. Journal of Neuro-Oncology, 2012, 109, 331-339.	1.4	43
57	Survival and prognostic factors of patients with unresectable glioblastoma multiforme. Anti-Cancer Drugs, 2003, 14, 305-312.	0.7	42
58	Association of platelet activation markers with cancer-associated venous thromboembolism. Platelets, 2016, 27, 80-85.	1.1	42
59	Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression. Anti-Cancer Drugs, 2005, 16, 1139-1143.	0.7	41
60	Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. Magnetic Resonance Imaging, 2012, 30, 139-147.	1.0	39
61	Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumors. Supportive Care in Cancer, 2012, 20, 175-183.	1.0	39
62	Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta OncolÃ³gica, 2011, 50, 630-635.	0.8	38
63	Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer. Thrombosis and Haemostasis, 2018, 118, 1875-1884.	1.8	38
64	Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times. PLoS ONE, 2013, 8, e55464.	1.1	38
65	Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables. Acta Neuropathologica Communications, 2018, 6, 135.	2.4	37
66	Neuromuscular electrical stimulation for a patient with metastatic lung cancerâ€"a case report. Supportive Care in Cancer, 2006, 14, 970-973.	1.0	36
67	Temozolomide Dosing Regimens for Glioma Patients. Current Neurology and Neuroscience Reports, 2012, 12, 286-293.	2.0	34
68	Tetrasomy 8 in acute monoblastic leukemia (AML-M5a) with myelosarcomatosis of the skin. Cancer Genetics and Cytogenetics, 1993, 71, 50-54.	1.0	31
69	Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Neuro-Oncology, 2013, 15, 112-121.	0.6	31
70	Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Anti-Cancer Drugs, 2003, 14, 437-442.	0.7	30
71	Epithelial Growth Factor Receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. Journal of Neuro-Oncology, 2008, 89, 211-218.	1.4	27
72	Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate. Journal of Neuro-Oncology, 2010, 97, 305-308.	1.4	27

#	Article	IF	Citations
73	Gamma Knife Radiosurgery in Recurrent Glioblastoma. Stereotactic and Functional Neurosurgery, 2016, 94, 265-272.	0.8	27
74	Neurological symptom burden impacts survival prognosis in patients with newly diagnosed nonâ€“small cell lung cancer brain metastases. Cancer, 2020, 126, 4341-4352.	2.0	27
75	Prognostic impact of genetic alterations and methylation classes in meningioma. Brain Pathology, 2022, 32, e12970.	2.1	27
76	Interferon-alfa-2b for meningioma. Lancet, The, 1995, 345, 331.	6.3	26
77	No prognostic impact of survivin expression in glioblastoma. Acta Neuropathologica, 2005, 109, 534-538.	3.9	26
78	Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status. European Radiology, 2017, 27, 1556-1567.	2.3	26
79	The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma. Radiotherapy and Oncology, 2017, 125, 228-233.	0.3	26
80	The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2396-2403.	3.3	25
81	Association of complete blood count parameters, dâ€dimer, and soluble Pâ€selectin with risk of arterial thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis, 2019, 17, 1335-1344.	1.9	25
82	Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. Journal of Neuro-Oncology, 2020, 148, 187-198.	1.4	25
83	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro-Oncology, 2022, 24, 755-767.	0.6	25
84	Malignant spinal cord compression in cerebral glioblastoma multiforme: a multicenter case series and review of the literature. Journal of Neuro-Oncology, 2012, 110, 221-226.	1.4	24
85	Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study. Wiener Klinische Wochenschrift, 2013, 125, 481-486.	1.0	24
86	Additive homeopathy in cancer patients: Retrospective survival data from a homeopathic outpatient unit at the Medical University of Vienna. Complementary Therapies in Medicine, 2014, 22, 320-332.	1.3	24
87	Assessing MGMT methylation status and its current impact on treatment in glioblastoma. CNS Oncology, 2015, 4, 47-52.	1.2	24
88	MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas. Pituitary, 2017, 20, 643-653.	1.6	24
89	Molecular biology of high-grade gliomas: what should the clinician know?. Chinese Journal of Cancer, 2014, 33, 4-7.	4.9	24
90	Cancer rehabilitation: current trends and practices within an Austrian University Hospital Center. Disability and Rehabilitation, 2020, 42, 2-7.	0.9	23

#	Article	IF	Citations
91	Prognostic relevance of p53 protein expression in glioblastoma. Oncology Reports, 2002, 9, 703-7.	1.2	23
92	Stabilization of a Progressive Hemangioblastoma under Treatment with Thalidomide. Journal of Neuro-Oncology, 2004, 66, 295-299.	1.4	22
93	Diversity of cytogenetic and pathohistologic profiles in glioblastoma. Cancer Genetics and Cytogenetics, 2006, 166, 46-55.	1.0	22
94	Response to imatinib as a function of target kinase expression in recurrent glioblastoma. SpringerPlus, 2014, 3, 111.	1.2	21
95	Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. Journal of Neuro-Oncology, 2012, 109, 323-330.	1.4	20
96	Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. Journal of Neurology, 2015, 262, 179-186.	1.8	20
97	Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study. Oncologist, 2020, 25, e1930-e1955.	1.9	20
98	Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine). Cancer Chemotherapy and Pharmacology, 2002, 49, 294-298.	1.1	19
99	Blood Alterations Preceding Clinical Manifestation of Glioblastoma. Cancer Investigation, 2012, 30, 625-629.	0.6	19
100	Cancer rehabilitation in Austriaâ€"aspects of Physical Medicine and Rehabilitation. Wiener Medizinische Wochenschrift, 2016, 166, 39-43.	0.5	19
101	Distributed changes of the functional connectome in patients with glioblastoma. Scientific Reports, 2020, 10, 18312.	1.6	19
102	Determining medical decision-making capacity in brain tumor patients: why and how?. Neuro-Oncology Practice, 2020, 7, 599-612.	1.0	19
103	Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors. Npj Vaccines, 2020, 5, 5.	2.9	19
104	Glioblastoma with Spinal Seeding. Strahlentherapie Und Onkologie, 2004, 180, 455-457.	1.0	18
105	Strength of skeletal muscle and self-reported physical performance in Austrian glioblastoma-patients. Wiener Klinische Wochenschrift, 2012, 124, 377-383.	1.0	18
106	Does 99mTc-Sestamibi in High-Grade Malignant Brain Tumors Reflect Bloodâ€"Brain Barrier Damage Only?. NeuroImage, 2000, 12, 109-111.	2.1	17
107	Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. ESMO Open, 2020, 5, e000863.	2.0	17
108	Translocation (16;21)(p11;q22) in acute monoblastic leukemia with erythrophagocytosis. Cancer Genetics and Cytogenetics, 1991, 54, 61-66.	1.0	16

#	Article	IF	Citations
109	Karyotypic Findings in Two Cases of Male Breast Cancer. Cancer Genetics and Cytogenetics, 2000, 121, 190-193.	1.0	16
110	Unexpected out-of-hospital deaths in persons aged 85 years or older: an autopsy study of 1886 patients. American Journal of Medicine, 2003, 114, 365-369.	0.6	16
111	Neuropathies associated with lymphomaâ€. Neuro-Oncology Practice, 2015, 2, 167-178.	1.0	16
112	Cytogenetic and comparative genomic hybridization findings in four cases of breast cancer after neoadjuvant chemotherapy. Cancer Genetics and Cytogenetics, 2003, 146, 161-166.	1.0	15
113	Frequent overexpression of ErbB â€“ receptor family members in brain metastases of nonâ€small cell lung cancer patients. Apmis, 2013, 121, 1144-1152.	0.9	15
114	Subclinical involvement of the liver is associated with prognosis in treatment naÃ¯ve cancer patients. Oncotarget, 2017, 8, 81250-81260.	0.8	15
115	Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 76-77.	0.3	15
116	Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies. Anticancer Research, 2013, 33, 1065-71.	0.5	15
117	Evidence of therapeutic efficacy of CCNU in recurrent choroid plexus papilloma. Journal of Neuro-Oncology, 2000, 49, 263-268.	1.4	14
118	Myxopapillary Ependymoma With Pleuropulmonary Metastases and High Plasma Glial Fibrillary Acidic Protein Levels. Journal of Clinical Oncology, 2011, 29, e756-e757.	0.8	14
119	Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens. Journal of Neuro-Oncology, 2013, 112, 347-354.	1.4	14
120	Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center. Wiener Klinische Wochenschrift, 2003, 115, 389-397.	1.0	13
121	Feasibility and toxicity of CCNU therapy in elderly patients with glioblastoma multiforme. Anti-Cancer Drugs, 2003, 14, 137-143.	0.7	13
122	Glioblastoma treatment using perphenazine to block the subventricular zoneâ€™s tumor trophic functions. Journal of Neuro-Oncology, 2014, 116, 207-212.	1.4	13
123	Advances in brain tumour classification and therapy. Nature Reviews Neurology, 2017, 13, 71-72.	4.9	13
124	Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma. Cancers, 2019, 11, 2020.	1.7	13
125	Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience. Radiology and Oncology, 2010, 44, 113-20.	0.6	11
126	Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma. Radiotherapy and Oncology, 2019, 130, 139-148.	0.3	11

#	Article	IF	Citations
127	Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients. Anti-Cancer Drugs, 2001, 12, 209-212.	0.7	10
128	Gender aspects of treatment and drug related toxicity in medical oncology. Wiener Medizinische Wochenschrift, 2006, 156, 534-540.	0.5	10
129	Pilot study on sex hormone levels and fertility in women with malignant gliomas. Journal of Neuro-Oncology, 2012, 107, 387-394.	1.4	10
130	Sorafenib for patients with pretreated recurrent or progressive high-grade glioma. Anti-Cancer Drugs, 2014, 25, 723-728.	0.7	10
131	GDFâ€15 in solid vs nonâ€solid treatmentâ€naÃ¯ve malignancies. European Journal of Clinical Investigation, 2019, 49, e13168.	1.7	10
132	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. European Journal of Cancer, 2020, 135, 150-158.	1.3	10
133	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. Cancer Immunology, Immunotherapy, 2021, 70, 3643-3650.	2.0	10
134	Case Report: Pregnancy in a patient with recurrent glioblastoma. F1000Research, 2013, 2, 246.	0.8	10
135	Complications of chemotherapy in neuro-oncology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 873-885.	1.0	9
136	High plasma-GFAP levels in metastatic myxopapillary ependymoma. Journal of Neuro-Oncology, 2013, 113, 359-363.	1.4	8
137	Milestones of the last 10Âyears. Memo - Magazine of European Medical Oncology, 2017, 10, 18-21.	0.3	8
138	Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study. Acta OncolÃ³gica, 2019, 58, 967-976.	0.8	8
139	Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. ESMO Open, 2019, 4, e000538.	2.0	7
140	Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. Translational Research, 2020, 215, 41-56.	2.2	7
141	The cancer survival indexâ€"A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. Cancer Medicine, 2022, 11, 3387-3396.	1.3	7
142	MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. Cancers, 2022, 14, 2563.	1.7	7
143	Microvessel density is not crucial for scintigraphic visualization of brain tumors using 99mTc-MIBI. Microvascular Research, 2004, 67, 218-222.	1.1	6
144	Temozolomide for recurrent or progressive high-grade malignant glioma: Results of an Austrian multicenter observational study. Wiener Klinische Wochenschrift, 2006, 118, 230-238.	1.0	6

#	Article	IF	Citations
145	Chemotherapy for malignant gliomas. Wiener Medizinische Wochenschrift, 2006, 156, 346-350.	0.5	6
146	Guiding Treatment Choices for Elderly Patients with Glioblastoma by a Comprehensive Geriatric Assessment. Current Oncology Reports, 2020, 22, 93.	1.8	6
147	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcomeâ€"including in elderly patients. Acta Neuropathologica Communications, 2022, 10, 39.	2.4	6
148	MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy. Cancers, 2022, 14, 1579.	1.7	6
149	Antiangiogenic Treatment of Meningiomas. Current Treatment Options in Neurology, 2015, 17, 359.	0.7	5
150	Evidence-based management of adult patients with diffuse glioma â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e430-e431.	5.1	5
151	Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience. Anti-Cancer Drugs, 2005, 16, 185-190.	0.7	4
152	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open, 2017, 2, e000166.	2.0	4
153	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. ESMO Open, 2020, 5, e000647.	2.0	4
154	PD1 and PD-L1 expression in glioblastoma.. Journal of Clinical Oncology, 2014, 32, 2011-2011.	0.8	4
155	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. ESMO Open, 2020, 5, e000880.	2.0	4
156	Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences. Anti-Cancer Drugs, 2004, 15, 495-8.	0.7	4
157	Double modulation of 5-fluorouracil by high-dose leucovorin and interferon?2b in advanced colorectal cancer. Journal of Cancer Research and Clinical Oncology, 1994, 120, 314-318.	1.2	3
158	Impaired hemorheology in patients with postmastectomy lymphedema. Breast Cancer Research and Treatment, 1996, 38, 283-288.	1.1	3
159	Cytogenetic Analysis and Fluorescence In Situ Hybridization in a Case of IgD Multiple Myeloma. Cancer Genetics and Cytogenetics, 1998, 105, 172-176.	1.0	3
160	Editorial: Behandlung von Glioblastomrezidiven. Wiener Medizinische Wochenschrift, 2011, 161, 1-2.	0.5	3
161	Evaluation of diagnostic and treatment approaches towards acute dyspnea in a palliative care setting among medical students at the University of Vienna. Wiener Medizinische Wochenschrift, 2012, 162, 18-28.	0.5	3
162	Light at the end of the tunnel: towards an effective drug therapy for surgery- and radiation-refractory meningioma. Neuro-Oncology, 2015, 17, 7-8.	0.6	3

#	Article	IF	Citations
163	Absence of CMV viremia in high-grade glioma patients under low dosage glucocorticoid treatment. Neuro-Oncology, 2017, 19, 1280-1282.	0.6	3
164	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. Blood, 2014, 124, 2859-2859.	0.6	3
165	Recurrent cardiac tamponade as first manifestation of gastric cancer. European Journal of Gastroenterology and Hepatology, 1998, 10, 621-622.	0.8	2
166	Immature and absolute platelet count changes and thrombocytopenia in malignant glioma. European Journal of Clinical Investigation, 2011, 41, 539-545.	1.7	2
167	The Association of Early Cognition Assessments and Progression-free Survival in Patients with Glioblastoma Multiforme. The Journal of Oncopathology, 2014, 1, 1-9.	0.1	2
168	Brain tumors â€“ other treatment modalities. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 547-560.	1.0	2
169	How should adult patients with neurofibromatosis 1 be managed?. Neuro-Oncology, 2018, 20, 721-722.	0.6	2
170	Reply to letter to the editor by Maddocks M. T. et al., â€œNeuromuscular electrical stimulation (NMES), a proactive supportive therapy or both?â€•regarding our publication â€œNeuromuscular electrical stimulation for a patient with metastatic lung cancerâ€”a case reportâ€•and recent experiences in glioblastoma patients. Supportive Care in Cancer, 2007, 15, 113-113.	1.0	1
171	First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?. CNS Oncology, 2013, 2, 473-474.	1.2	1
172	Geriatric oncology: questions, answers and guidelines. Memo - Magazine of European Medical Oncology, 2021, 14, 24-28.	0.3	1
173	Will mastering ferroptosis allow treating refractory meningiomas?. Neuro-Oncology, 2021, 23, 1989-1990.	0.6	1
174	A randomized clinical trial for the treatment of glioblastoma multiforme with the individualized dendritic cell-based cancer immunotherapy AV0113.. Journal of Clinical Oncology, 2014, 32, 2052-2052.	0.8	1
175	Drug therapy for recurrent, progressive, atypical, and malignant meningiomas. Memo - Magazine of European Medical Oncology, 2012, 5, 218-222.	0.3	0
176	News from the Neuro-Oncology front. Memo - Magazine of European Medical Oncology, 2012, 5, 169-170.	0.3	0
177	The End-of-Life in patients with glioma and their families. Memo - Magazine of European Medical Oncology, 2012, 5, 233-235.	0.3	0
178	Conference Scene: Neuro-oncology insights from European Society of Medical Oncology 2012. CNS Oncology, 2013, 2, 29-31.	1.2	0
179	NTCT-09IGF-1 IS NOT ELEVATED IN PATIENTS WITH HGG TREATED WITH RADIOCHEMOTHERAPY. Neuro-Oncology, 2015, 17, v174.1-v174.	0.6	0
180	Is dosing in oncology gender-sensitive?. Memo - Magazine of European Medical Oncology, 2015, 8, 5-10.	0.3	0

#	Article	IF	Citations
181	Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma?. EBioMedicine, 2018, 29, 9-10.	2.7	0
182	MNGI-28. CORRELATION OF METHYLATION CLASS AND GENETIC ALTERATIONS WITH PROGRESSION FREE SURVIVAL IN MENINGIOMA. Neuro-Oncology, 2018, 20, vi155-vi155.	0.6	0
183	Elderly patients with cancer. Memo - Magazine of European Medical Oncology, 2021, 14, 1-2.	0.3	0
184	High Soluble P-Selectin and Low Platelet Count as Thrombosis Risk Markers in Glioma Patients.. Blood, 2009, 114, 2985-2985.	0.6	0
185	Correlation of large brain edema with favorable prognosis in patients with single brain metastases.. Journal of Clinical Oncology, 2012, 30, 2053-2053.	0.8	0
186	Factor V Leiden Mutation Increases the Risk of Venous Thromboembolism in Cancer Patients â€“ Results From the Vienna Cancer and Thrombosis Study (CATS).. Blood, 2012, 120, 2253-2253.	0.6	0
187	Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).. Journal of Clinical Oncology, 2013, 31, TPS2103-TPS2103.	0.8	0
188	QOL and neurocognitive functions in patients with GBM.. Journal of Clinical Oncology, 2014, 32, 2062-2062.	0.8	0
189	Ausgangslage fÃ¼r RehabilitationsmaÃŸnahmen bei HirntumorpatientInnen. , 2020, , 227-236.		0
190	NIMG-13. RESPONSE ASSESSMENT IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL-BASED IMMUNOTHERAPY: A COMPARATIVE ANALYSIS OF MACDONALD, RANO, MRANO, IRANO AND VOLUMETRIC MEASUREMENTS. Neuro-Oncology, 2021, 23, vi130-vi130.	0.6	0